The partnership with Solgar for the use of NIAGEN in a new product line is directly related to ChromaDex's core business of developing and marketing dietary supplements. This collaboration could lead to increased product visibility, higher sales, and potentially positive investor sentiment towards CDXC, thus likely to have a positive short term impact on its stock price.